The GRPR Antagonist [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Gastrin-releasing peptide receptors (GRPRs) are overexpressed in the majority of primary prostate tumors and in prostatic lymph node and bone metastases. Several GRPR antagonists were developed for SPECT and PET imaging of prostate cancer. We previously reported a preclinical evaluation of the GRPR...

Full description

Bibliographic Details
Main Authors: Ayman Abouzayed, Jesper Borin, Fanny Lundmark, Anastasiya Rybina, Sophia Hober, Roman Zelchan, Vladimir Tolmachev, Vladimir Chernov, Anna Orlova
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/13/9/1611